ring finger protein 103Genealiases: HKF-1 · KF-1 · KF1 · ZFP-103 · ZFP103
Q-omics provides the consensus-scored RNF103 profile across patient tissues and cancer cell-line models. RNF103 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RNF103 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, RNF103 RNA expression shows 21,429 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, KICH, and THYM as cancer lineages where RNF103 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF103 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF103 survival associations across molecular data types. RNF103 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF103 RNA expression–survival associations across cancer types. High RNF103 expression shows unfavorable associations in KIRP, but favorable associations in KIRC, SKCM, BRCA, BLCA and SARC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RNF103 RNA expression.
This table summarizes RNF103 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RNF103. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF103 shows lower tumor expression in KICH, BLCA, UCEC and COAD and higher tumor expression in LIHC and BRCA. The KICH box plot shows higher RNF103 RNA expression in normal versus tumor tissue (log2 FC = −0.942, t-test p < 0.001).
This table shows molecular features associated with RNF103 in patient tissues and cancer cell lines. In patient samples, RNF103 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF103 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
